26.04.2022 - 28.04.2022Hilton Boston Back Bay, 40 Dalton Street, 02115 Boston, USA
Time: 9:00 AM - 4:00 PM
Kongressthemen FcRn, Fcγ, and IgG studies have been propelled by drug developers recently after Argenx’s potential FDA’s approval of first-in-class FcRn antagonist efgartigimod, AstraZeneca-Alexion’s $39 billion deal, and positive clinical updates from UCB’s Rozanolixizumab. Successful modulation of the Fc pathways and optimized IgG antibodies have proven clinical utility and demonstrate significant therapeutic potential with more players poised to bring their candidates through clinic.
